Why Is TYRA BIOSCIENCES INC (TYRA) Stock Up Today?
By the Top Tier Newswire AI Desk · September 4, 2026 at 10:58 AM ET · reviewed against 1 wire stories
TYRA BIOSCIENCES INC (TYRA) is up +16.17% in the latest session. Our newswire has captured 1 story on TYRA across 1 source in the last 36 hours, with AI sentiment reading mixed (avg 56/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why TYRA stock is up today
TYRA stock surged 16.17% to $28.88 in a volatile session driven by the announcement that Tyra Biosciences will host a conference call on September 9 to discuss initial results from the Phase 2 SURF302 study of oral Dabogratinib for IR NMIBC. The stock opened with a modest 1.0% gap up and climbed steadily throughout the session, reaching a high of $29.35 before settling at $28.86. The move reflects investor anticipation of the clinical data and the company's progress in its pipeline.
What Happened
Tyra Biosciences announced it will host a conference call to discuss initial results from the Phase 2 SURF302 study of oral Dabogratinib for the treatment of intermediate-risk non-muscle invasive bladder cancer (IR NMIBC). The call is scheduled for September 9 and will include a webcast. The company is a clinical-stage biotechnology firm focused on developing precision medicines. The announcement follows a recent earnings report for the second quarter that showed an EPS of $(0.69), which missed the $(0.65) estimate. Despite the earnings miss, the clinical development update appears to have shifted investor focus to the potential of Dabogratinib.
What The Data Shows
The stock has traded between $24.51 and $29.35 during the session, with a volume of 0.3 million shares, which is 0.4 times the 3-month daily average. The unusual options activity includes two notable prints, with $2.0 million in call premium and no put premium. The largest single print was $1.4 million. Additionally, the stock printed 22 fresh 52-week highs on September 4. The 30-day average sentiment score is 52 out of 100, while the last 7 days show an improved score of 56 out of 100.
What To Watch
Investors should monitor the conference call on September 9 when Tyra Biosciences will present initial results from the SURF302 study. The data could influence further investor sentiment and potentially impact the stock's trajectory.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
TYRA · Sep 4 session (5-min) · +15.25% vs prior close · updated 8:56 PM ETAI sentiment, last 36h · averaged over 1 story · 56/100 bullish
The headlines behind the move
Story flow · 1 story on the wire, last 36h · hover or tap a dot for the headline
9d agoPR NewswireBULLISH 56Product/PR
Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026
CARLSBAD, Calif., Sept. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →